HK Stock Market Move | Zai Lab (09688) rose by over 4% and announced a partnership with Bristol-Myers Squibb to develop innovative dual DLL3-targeted combination therapy.

ZAI LAB (09688) rose more than 4%, as of the time of publication, it had risen by 3.84%, to HK$18.1, with a trading volume of HK$82.7149 million. On the news front, on April 15th, according to ZAI LAB's official WeChat account, the company announced a clinical collaboration with Bristol-Myers Squibb to develop an innovative dual DLL3 targeted therapy. The phase Ib/II study will evaluate the safety, tolerability, and preliminary clinical activity of ZAI LAB's DLL3-targeted ADC zocilurtatug pelitecan (zoci, formerly known as ZL-1310) in combination with Bristol-Myers Squibb's DLL3/CD3 T cell engager obrixtamig. Zocilurtatug pelitecan (zoci) is a DLL3-targeted ADC developed by ZAI LAB, designed to deliver potent cytotoxic payloads to DLL3-positive tumor cells for the treatment of ES-SCLC. The latest global phase I results show that zoci demonstrates potent and durable responses in patients with ES-SCLC who have previously received treatment, including those with brain metastases, with good safety. Based on this, the project has progressed to a global phase III registration study.